IL33 and infection: We hypothesized that ILC2s respond to IL-33 to promote anti-toxin B antibodies and protect from reinfection, in part due to their known role in adaptive immunity (23) and due to the observed increase in ILC2s in the IL-33–treated group after infection in the MLN and colon (Figure 5, A–D, and Supplemental Figure 6, A and B).